摘要
目的探讨帕妥珠单抗联合白蛋白结合型紫杉醇和卡铂治疗人表皮生长因子受体2(HER2)阳性晚期乳腺癌患者的疗效。方法根据治疗方式的不同将108例HER2阳性晚期乳腺癌患者分为观察组(n=63)和对照组(n=45),对照组患者给予白蛋白结合型紫杉醇联合卡铂治疗,观察组患者给予帕妥珠单抗联合白蛋白结合型紫杉醇和卡铂治疗。比较两组患者的肿瘤标志物[癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原15-3(CA15-3)]水平、血管内皮生长因子(VEGF)水平、临床疗效及不良反应发生情况。结果治疗后,两组患者CEA、CA125、CA15-3、VEGFA、VEGFB水平均低于本组治疗前,观察组患者CEA、CA125、CA15-3、VEGFA、VEGFB水平均低于对照组,差异均有统计学意义(P﹤0.05)。观察组患者的疾病控制率高于对照组,差异有统计学意义(P﹤0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P﹥0.05)。结论帕妥珠单抗联合白蛋白结合型紫杉醇和卡铂治疗HER2阳性晚期乳腺癌患者的疗效显著,可降低肿瘤标志物及VEGFA、VEGFB水平,且具有一定的安全性。
Objective To explore the therapeutic effect of pertuzumab combined with albumin-bound paclitaxel and carboplatin in patients with human epidermal growth factor receptor 2(HER2)-positive advanced breast cancer.Method According to different treatment methods,108 patients with HER2-positive advanced breast cancer were divided into observation group(n=63)and control group(n=45).Patients in the control group were treated with albumin-bound paclitaxel combined with carboplatin,and patients in the observation group were treated with pertuzumab combined with albumin-bound paclitaxel and carboplatin.The tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),carbohydrate antigen 15-3(CA15-3)]levels,vascular endothelial growth factor(VEGF)levels,clinical efficacy and adverse reactions were compared between the two groups.Result After treatment,the CEA,CA125,CA15-3,VEGFA and VEGFB levels in both groups were lower than those before treatment,and the CEA,CA125,CA15-3,VEGFA and VEGFB levels in observation group were lower than those in control group,and the differences were statistically significant(P<0.05).The disease control rate of observation group was higher than that of control group,and the difference was statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Pertuzumab combined with albumin-bound paclitaxel and carboplatin have significant efficacy in the treatment of HER2-positive advanced breast cancer patients,which can reduce the levels of tumor markers and VEGFA,VEGFB,and has a certain safety.
作者
李鸿业
张菡
温琳琳
梁丽
LI Hongye;ZHANG Han;WEN Linlin;LIANG Li(Department of Pharmacy,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,He’nan,China;Department of Oncology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,He’nan,China)
出处
《癌症进展》
2024年第18期1994-1997,共4页
Oncology Progress
